# QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

> **NCT05160974** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 679 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05160974
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 679 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160974, "QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05160974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*